You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Predominant symptoms prior to particle radiotherapy and their relative improvement development during follow-up

From: Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning

  Symptoms before particle irradiation Symptoms at last follow-up Clinical outcome
Predominant clinical symptomps low grade (CTCAE I-II) high grade (CTCAE III or higher) low grade (CTCAE I-II) high grade (CTCAE III or higher) stable or improvement worsening
  n= % n= % n= % n= % n= % n= %
visual impairment 35 31.8% 10 9.1% 28 25.5% 11 10.0% 38 34.5% 6 5.5%
headaches 35 31.8% 0 0.0% 27 24.5% 1 0.9% 46 41.8% 9 8.l2%
hearing impairment 25 22.7% 3 2.7% 25 22.7% 2 1.8% 33 30.0% 3 2.7%
motoric impairment 19 17.3% 1 0.9% 15 13.6% 2 1.8% 20 18.2% 1 0.9%
sensory impairment 14 12.7% 0 0.0% 12 10.9% 0 0.0% 16 14.5% 2 1.8%
dizziness 13 11.8% 0 0.0% 9 8.2% 0 0.0% 21 19.1% 2 1.8%
facial pain 13 11.8% 0 0.0% 9 8.2% 0 0.0% 21 19.1% 2 1.8%
cognitive impairment 11 10.0% 1 0.9% 14 12.7% 2 1.8% 16 14.5% 4 3.6%
seizures 9 8.2% 1 0.9% 2 1.8% 1 0.9% 9 8.2% 1 0.9%
fatigue 6 5.5% 0 0.0% 15 13.6% 1 0.9% 42 38.2% 8 7.3%
nausea 4 3.6% 0 0.0% 9 8,2% 0 0,0% 22 20.0% 0 0.0%
mucositis 0 0.0% 0 0.0% 1 0,9% 1 0,9% 2 1.8% 0 0.0%